Weekly Recap | Profusa +14.14%, ISO certification news drives surge
I'm LongbridgeAI, I can summarize articles.Profusa (PFSA) rose 14.14% this week to close at $2.18, outperforming the S&P 500 by roughly 12.93 percentage points. The weekly amplitude reached 126.15%, with a sharp rally-and-fade pattern: Monday opened near $1.87, Tuesday and Wednesday ground higher, Thursday surged to $4.18 on ISO 13485 certification news before settling at $3.03, and Friday gave back to $2.18. Average daily volume of 17.
The Week
Profusa (PFSA) rose 14.14% this week to close at $2.18, outperforming the S&P 500 by roughly 12.93 percentage points. The weekly amplitude reached 126.15%, with a sharp rally-and-fade pattern: Monday opened near $1.87, Tuesday and Wednesday ground higher, Thursday surged to $4.18 on ISO 13485 certification news before settling at $3.03, and Friday gave back to $2.18. Average daily volume of 17.55m shares was far above the prior 60-day median of 231k, pointing to a widening divide in positioning.
Key Events
The company-specific story this week centred on regulatory and product-certification developments. On Monday, shareholders voted to authorise a potential reverse stock split amendment, keeping capital-structure options open. On Thursday, the firm announced significant progress towards CE Mark for its Lumee Oxygen Platform, with ISO 13485 certification expected in early October; the stock briefly gained more than 97% intraday on elevated volume. Friday saw a pullback of over 20%, with heavy turnover signalling disagreement. The name repeatedly appeared on lists of the most active healthcare stocks during pre-market and intraday sessions.
The Week Ahead
The macro calendar is busy: Dallas Fed manufacturing activity lands on Monday 28 September, followed on Tuesday 29 September by FHFA house prices, Case-Shiller 20-city home prices, JOLTS job openings and consumer confidence. On the company side, valuation remains in negative territory at -0.03x P/E and -0.05x P/B. What to watch: whether ISO 13485 certification is formally secured in early October, and whether further steps on the reverse split are announced.
In Short
This week’s tension was between regulatory momentum and weak financials inside a highly volatile tape. The positive ISO 13485 decision pushed the Lumee Oxygen Platform’s CE Mark process forward, while turnover rate hit 420.34% and the latest session showed large and medium orders as net buyers, with small orders as net sellers. P/E and P/B are both negative, so the firm is still loss-making. The next test is whether certification arrives on schedule in early October and whether participation holds up after such extreme churn.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.